A 68-year-old woman with hypertension on lisinopril and a 35-year-old man with DKA both present with serum potassium 6.5 mEq/L. Which clinical finding best distinguishes ACE inhibitor-induced hyperkalemia from hyperkalemia due to metabolic acidosis?

Explanation

## Distinguishing ACE Inhibitor Hyperkalemia from DKA Hyperkalemia ### Two Distinct Mechanisms **ACE inhibitor hyperkalemia:** - Mechanism: ACE inhibitors block angiotensin II → ↓ aldosterone secretion → ↓ renal K⁺ excretion in collecting duct - Aldosterone is **suppressed** (low) - Acid-base status: Usually normal pH - Serum glucose: Normal; **no ketonemia** **DKA hyperkalemia:** - Mechanism: H⁺ enters cells → K⁺ exits (transcellular shift) + insulin deficiency impairs cellular K⁺ uptake + volume depletion - Acid-base status: Severe metabolic acidosis (pH <7.3, low HCO₃⁻) - Serum glucose: Markedly elevated (>250 mg/dL); **ketonemia present** ### Key Discriminating Feature: Hyperglycemia and Ketonemia **Key Point:** The question asks what **best distinguishes** ACE inhibitor-induced hyperkalemia from hyperkalemia due to metabolic acidosis (DKA). The best clinical discriminator is the presence of **hyperglycemia and ketonemia** in DKA, which are entirely absent in ACE inhibitor-induced hyperkalemia. | Feature | ACE Inhibitor | DKA | |---------|---------------|-----| | **Hyperglycemia** | Absent | **Present (>250 mg/dL)** | | **Ketonemia** | Absent | **Present** | | **Aldosterone** | ↓ Low | ↑ High (compensatory) | | **pH** | Normal (7.35–7.45) | Low (<7.3) | | **HCO₃⁻** | Normal (22–26 mEq/L) | Low (<15 mEq/L) | ### Why Hyperglycemia + Ketonemia Is the Best Clinical Discriminator 1. **Pathognomonic for DKA:** Hyperglycemia and ketonemia are the defining clinical and biochemical hallmarks of DKA. Their presence immediately identifies the cause of hyperkalemia as DKA-related metabolic acidosis. 2. **Readily available at bedside:** Blood glucose and urine/serum ketones are rapid, routine tests — far more accessible clinically than aldosterone levels (which require specialized assays and are not routinely ordered acutely). 3. **Completely absent in ACE inhibitor hyperkalemia:** A patient on lisinopril with no diabetes will have normal glucose and no ketones, making this a clean binary discriminator. ### Why Option A (Aldosterone Levels) Is Incorrect as the Best Answer Option A states "Elevated aldosterone levels in ACE inhibitor cause; low aldosterone in DKA" — this is **factually reversed**. ACE inhibitors **suppress** aldosterone (low), while DKA causes volume depletion → RAAS activation → **elevated** aldosterone. Beyond being stated backwards in the option, aldosterone measurement is not a routine clinical test and is not used as a first-line discriminator in acute settings. **High-Yield:** In DKA, despite hyperkalemia, total body K⁺ is depleted due to osmotic diuresis and vomiting. Treatment with insulin and fluids will cause a dramatic drop in serum K⁺ as K⁺ re-enters cells — always monitor and replete K⁺ during DKA treatment. **Clinical Pearl:** ECG changes (peaked T waves, prolonged PR) are identical at the same serum K⁺ level regardless of etiology and therefore do NOT distinguish the two causes. [cite: Harrison 21e Ch 280, 396; KD Tripathi 8e Ch 34]